OSUR logo

OraSure Technologies Inc. (OSUR)

$3.97

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OSUR

Market cap

$273328755

EPS

-1.04

P/E ratio

--

Price to sales

1.94

Dividend yield

--

Beta

1.003454

Price on OSUR

Previous close

$4.03

Today's open

$4.04

Day's range

$3.96 - $4.10

52 week range

$2.08 - $4.58

Profile about OSUR

CEO

Carrie Eglinton Manner

Employees

501

Headquarters

Bethlehem, PA

Exchange

Nasdaq Global Select

Shares outstanding

68848553

Issue type

Common Stock

OSUR industries and sectors

Healthcare

Medical Equipment & Supplies

News on OSUR

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.

news source

GlobeNewsWire • Jul 22, 2026

news preview

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.

news source

GlobeNewsWire • Jul 21, 2026

news preview

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.

news source

GlobeNewsWire • Jun 11, 2026

news preview

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 7, 2026

news preview

OraSure Announces First Quarter 2026 Financial Results

BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.

news source

GlobeNewsWire • May 6, 2026

news preview

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.

news source

GlobeNewsWire • Apr 22, 2026

news preview

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.

news source

GlobeNewsWire • Apr 17, 2026

news preview

Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says

Activist investor Altai Capital Management called on OraSure Technologies ​to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter ‌seen by Reuters.

news source

Reuters • Mar 17, 2026

news preview

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight.

news source

GlobeNewsWire • Mar 17, 2026

news preview

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure.

news source

Business Wire • Mar 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in OraSure Technologies Inc.

Open an M1 investment account to buy and sell OraSure Technologies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OSUR on M1